Stereotactic Volumetric Radiotherapy in Prostate Cancer

Inclusion Criteria: * Histology of prostate adenocarcinoma * Age≥ 18 years * Life expectancy≥ 10 years * Clinical negative nodes (N0) * No metastasis presence (M0) * No previous pelvic radiation therapy * Total PSA≤10 ng/ml * Gleason score ≤ 6 * T1-2 * ≤ 3 positive biopsy at prostatic mapping * Signed informed consent Exclusion Criteria: * Positive nodes (N+) or metastatic disease (M+) * Inflammatory bowel disease, collagen- vascular disorders or active autoimmune disorders * Anticoagulant treatment in progress * Hip or pelvic presence of medical devices that could prevent a correct image acquisition * Symptomatic haemorrhoidal disease * Adverse reactions to iodinate or paramagnetic contrast media * Previous malignant cancer, except basocellular skin tumour or other tumours healed since 5 years * Previous pelvic radiotherapy * Psychiatric disorder that preclude to obtain informed consent